An interim perspective on the removal of encainide and flecainide from the cardiac arrhythmia suppression trial.
Coyle
J D
JD
College of Pharmacy, Ohio State University, Columbus 43210.
Schaal
S F
SF
D000813:Anilides / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D016700:Encainide; D004992:Ethics, Medical; D005424:Flecainide / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D005424:Flecainide; D016700:Encainide